Lyon Martha E, Lyon Andrew W
Calgary Laboratory Services, Calgary, Alberta, Canada.
J Diabetes Sci Technol. 2012 May 1;6(3):656-8. doi: 10.1177/193229681200600321.
The article entitled "Hematocrit Compensation in Electrochemical Blood Glucose Monitoring Systems" by Teodorczyk and colleagues in this issue of Journal of Diabetes Science and Technology demonstrates that the OneTouch(®) Verio™ glucose meter meets current regulatory expectations for glucose meter performance and is relatively free from interference by hematocrit. The lack of influence of hematocrit on whole blood glucose results is a valuable attribute for hospital applications, where greater variation of hematocrit among patients is anticipated. The choice of reference method for evaluation of glucose meters is an important consideration, and it is not clear to what extent reference methods used to evaluate glucose meters are also free from hematocrit interferences.
特奥多奇克及其同事在本期《糖尿病科学与技术杂志》上发表的题为《电化学血糖监测系统中的血细胞比容补偿》的文章表明,OneTouch(®) Verio™血糖仪符合当前血糖仪性能的监管要求,且相对不受血细胞比容的干扰。血细胞比容对全血血糖结果缺乏影响,这对于医院应用来说是一个有价值的特性,因为预计患者之间的血细胞比容差异会更大。评估血糖仪时参考方法的选择是一个重要考虑因素,目前尚不清楚用于评估血糖仪的参考方法在多大程度上也不受血细胞比容干扰。